Strategic objectives

• To advance the pathophysiological understanding of ischemia-reperfusion injury in the context of kidney transplantation, through translational research from the experimental to the clinical setting.
• To identify biomarkers that allow for the prediction of injector viability and function after kidney transplantation.
• To advance the development of pharmacological modulation models of ischemia-reperfusion injury during kidney preservation in perfusion devices.
• To evaluate the diagnostic yield and therapeutic efficacy of new diagnostic and treatment techniques for prostate cancer: MRI-ultrasound fusion biopsy using navigation-guided systems, focal ablation techniques for prostate cancer, and intraoperative neurostimulation of neurovascular bundles in prostate surgery.
• To participate in multicenter studies for the evaluation of new molecules in the treatment of prostate cancer.
• To participate in multicenter studies and cooperative groups for the study and treatment of functional and oncological bladder pathology. To search for biomarkers that predict treatment response and disease recurrence, as well as to molecularly characterize the neoplasia and the tumor microenvironment in renal and urothelial cancer.

Research lines

• Kidney transplantation and preservation in experimental and clinical settings.
• Diagnostic and therapeutic innovation in uro-oncology: prostate, kidney, urothelial, and adrenal cancers.
• Kidney stones: epidemiological aspects and associated endothelial dysfunction.
• Prehabilitation of surgically frail cancer patients from an anesthesiology perspective.
• Development of predictive models for self-learning and survival based on biomarkers.